What Factors Should Aesthetic Clinics Consider Regarding Pigment Depth And Skin Type When Treating Melasma With Advanced Laser And Light Systems? Key Strategies For Safe And Effective Treatment.

Pigment depth and Fitzpatrick skin type should determine whether, when, and how an aesthetic clinic uses energy-based treatment for melasma. Epidermal, dermal, and mixed melasma respond differently to light and laser systems, while darker phototypes, particularly Fitzpatrick III–V, have a greater risk of thermal injury, post-inflammatory hyperpigmentation (PIH), hypopigmentation, and rebound pigmentation. Practitioners should therefore confirm the likely pigment depth, stabilize melanocyte activity with topical therapy and sun protection, and select conservative wavelengths and treatment techniques accordingly.

Melasma is not simply a superficial brown discoloration. Its depth, vascular contribution, and the patient’s baseline melanogenic activity must guide device selection, energy settings, cooling, treatment intervals, and expectations.

Why Pigment Depth Matters

Epidermal Melasma

Epidermal melanin is closer to the surface and may respond more readily to treatments that target superficial pigment. However, high melanin absorption at shallow wavelengths also increases epidermal heating, particularly in darker skin.

Shorter wavelengths, such as 532 nm, are highly absorbed by melanin but have limited penetration. They are generally more appropriate for superficial lesions such as freckles or solar lentigines than for routine melasma treatment.

Dermal Melasma

Dermal pigment lies deeper and is more difficult to clear completely. Longer wavelengths, particularly 1064 nm Nd:YAG systems, penetrate further while producing less absorption in epidermal melanin.

This relative epidermal protection can be valuable in darker skin types. It does not eliminate risk, however, because excessive fluence, repeated passes, or cumulative thermal exposure can still aggravate melasma.

Mixed Melasma

Mixed melasma contains both epidermal and dermal components. It may show only partial improvement when a device addresses one compartment while leaving the other largely unaffected.

Clinicians should avoid interpreting incomplete early response as a reason to escalate energy aggressively. Mixed disease often requires a multimodal plan involving topical therapy, photoprotection, and carefully selected adjunctive procedures.

Match the Device to the Patient

Fitzpatrick Skin Type III–V

Darker skin contains more epidermal melanin, which competes with the intended target for laser or light absorption. This raises the risk of PIH, uneven hypopigmentation, and prolonged dyschromia after treatment.

Lower fluence, effective cooling, conservative pulse delivery, and careful treatment spacing are essential. A deeper-penetrating wavelength with lower epidermal melanin absorption, such as 1064 nm, may offer a more appropriate safety profile for selected indications.

Lighter Phototypes

Lighter phototypes generally have less epidermal melanin competing for energy absorption. This can broaden the range of usable devices and reduce, but not remove, the risk of PIH.

The clinician should still treat melasma as a relapse-prone inflammatory pigmentary disorder. A lighter skin type does not justify aggressive single-pass treatment or prolonged heating.

Skin Type Is Not the Only Variable

Fitzpatrick classification provides a useful risk framework, but it does not independently establish pigment depth or predict treatment response. The clinical pattern, history of PIH, current tanning, hormonal influences, inflammation, and previous procedures should also inform the treatment decision.

A precise diagnostic skin evaluation should precede energy treatment. The assessment should establish whether the appearance is predominantly epidermal, dermal, mixed, or accompanied by a visible vascular component.

Prepare the Skin Before Energy Treatment

Stabilize Melanocyte Activity

Topical depigmenting treatment and strict broad-spectrum sun protection remain the foundation of melasma management. For refractory cases being considered for laser or light treatment, the reference material recommends at least six weeks of pre-treatment to suppress melanocyte activity.

Treating actively reactive melasma without adequate preparation increases the likelihood that thermal inflammation will stimulate further pigmentation.

Confirm Adherence and Stability

The clinician should assess whether the patient is consistently using photoprotection and the prescribed topical regimen. Recent tanning, active dermatitis, irritation, or a history of poor healing should prompt additional caution or postponement.

Energy-based treatment should be considered an adjunct or second-line option when topical therapy alone is insufficient, ineffective, or poorly tolerated.

Patch Test Before Broad Treatment

A localized patch test is especially important for darker phototypes, patients with previous PIH, and treatments involving broadband light or fractional resurfacing. The test area should be observed for immediate reactions and delayed pigmentary change before treating larger regions.

A patch test does not guarantee a complication-free treatment, but it provides useful evidence about the patient’s response to the proposed settings and device.

Select Conservative Treatment Strategies

Low-Fluence 1064 nm Laser Toning

Low-fluence 1064 nm Q-switched Nd:YAG treatment is commonly considered for melasma because it reaches deeper tissue while limiting epidermal melanin absorption. The cited protocol uses large spot sizes of approximately 6–8 mm, fluences around 1.6–2.3 J/cm², and intervals of one to two weeks, with mild erythema as the endpoint.

These figures are not universal prescriptions. Device architecture, spot profile, pulse characteristics, cooling, skin type, and clinical response must determine the final settings.

Fractional Non-Ablative Systems

Fractional non-ablative systems, including 1540/1550 nm Er:Glass platforms, can support pigment clearance while limiting treatment to microscopic columns. They may be useful when topical therapy has not achieved sufficient improvement or when a less destructive approach is preferred.

The intended response should be gradual. Low pulse energy and controlled treatment density are generally more appropriate than high-energy resurfacing for a disorder that is easily reactivated by inflammation.

Fractional Ablative Lasers

Fractional Er:YAG or CO2 systems can remove or disrupt epidermal pigment and may help disperse dermal melanin. Their microscopic treatment columns can facilitate pigment extrusion through microscopic epidermal necrotic debris, often referred to as MENDs.

Because each fractional zone removes only a small amount of pigment, these systems should be selected carefully and usually treated as an adjunct or alternative when conservative approaches are inadequate. High-energy treatment can create unnecessary inflammation and worsen the underlying disorder.

IPL and Vascular Components

IPL may be considered for selected refractory cases, but broadband energy can be absorbed nonspecifically by epidermal melanin. Uniform pulse delivery, suitable cutoff filters, conservative fluence, cooling, and patch testing are important risk controls.

When telangiectasia or a prominent vascular component is present, vascular-directed treatment may be incorporated into the plan. The vascular contribution should be assessed rather than assumed, since not every case of melasma requires vascular treatment.

Understanding the Trade-Offs

More Energy Does Not Mean More Clearance

Aggressive treatment can produce a visible short-term reduction in pigment while increasing inflammation and delayed recurrence. Melasma is dynamic, and thermal irritation may trigger additional melanogenesis.

The practical objective is controlled improvement with minimal inflammation, not the strongest immediate endpoint.

Fractional Treatment Requires Patience

Fractional systems distribute treatment across microscopic zones, so clearance per session is limited. Multiple sessions may be required, and improvement should be evaluated over time rather than judged immediately after peeling or transient darkening.

Patients should understand that fractional treatment may be valuable for selected resistant cases but is not a substitute for ongoing topical management and photoprotection.

Darker Skin Has a Narrower Safety Margin

Darker phototypes are not automatically unsuitable for laser or light treatment. They require more careful energy selection because epidermal melanin increases the chance of unintended absorption and pigmentary complications.

Lower fluence, appropriate wavelength selection, conservative passes, cooling, and adequate intervals are central to reducing risk.

Rebound Pigment and Mottled Hypopigmentation

Repeated or prolonged low-fluence laser toning can still cause mottled hypopigmentation or rebound hyperpigmentation if treatment is excessive. The mild erythema endpoint should not be converted into a justification for repeated passes or escalating energy during the same session.

Treatment should be stopped or adjusted when the response becomes excessive, uneven, or inconsistent with the intended endpoint.

Patient Expectations Must Be Specific

Temporary darkening, peeling, and erythema can occur for several days after treatment. Patients should also be told that multiple sessions may be needed and that maintenance therapy and sun avoidance remain important after visible improvement.

Deeper or larger areas and some fractional procedures may require local anesthesia or nerve blocks for comfort, depending on the device and treatment intensity.

How to Apply This to Your Clinic

The treatment decision should be based on a documented assessment rather than on pigment color alone.

If your primary focus is epidermal pigment: Consider superficial-targeting approaches only after confirming the diagnosis and using conservative settings appropriate to the patient’s phototype.
If your primary focus is dermal or mixed pigment: Favor strategies capable of reaching deeper tissue, such as carefully selected low-fluence 1064 nm or fractional non-ablative treatment, while setting expectations for gradual improvement.
If your primary focus is treating Fitzpatrick III–V skin: Use lower fluence, effective cooling, patch testing, cautious intervals, and wavelengths that reduce epidermal melanin absorption.
If your primary focus is refractory melasma: Use energy-based devices as adjuncts or second-line treatments after adequate topical preparation and photoprotection.
If your primary focus is minimizing PIH and relapse: Prioritize melanocyte stabilization, conservative clinical endpoints, and avoidance of aggressive high-energy passes.
If your primary focus is a vascular presentation: Assess for telangiectasia or other vascular features before adding a vascular laser component.

The safest and most effective melasma protocols begin with accurate depth assessment, respect the patient’s skin type, and treat inflammation control as seriously as pigment clearance.

Summary Table:

Factor	Consideration
Pigment Depth	Epidermal, dermal, and mixed melasma respond differently to wavelengths and energy settings.
Skin Type	Darker phototypes (III–V) have higher risk of PIH; choose wavelengths with lower epidermal melanin absorption.
Pretreatment	Stabilize melanocytes with topical therapy and sun protection for at least 6 weeks.
Device Selection	Low-fluence 1064 nm, fractional non-ablative, or fractional ablative lasers may be used conservatively.
Treatment Strategy	Use lower fluence, cooling, patch testing, and conservative endpoints to minimize inflammation and recurrence.

Ensure safe and effective melasma treatment with advanced laser systems from BELIS. Our professional-grade devices, including Nd:YAG and fractional lasers, are designed for clinics and premium salons. Contact us today to learn how we can help you achieve optimal results while minimizing risks for your patients. Get in touch with our experts!